There was a clear differential protein enrichment between EV and SP fractions, of which gene set enrichment analysis showed differential biological functions and cellular origin. Moreover, urine samples before and after local prostate cancer treatment were enriched in different proteins. This applied to both the EV and SP fractions. A significant over-representation of proteins involved in RNA and protein metabolism was found in uEV prior to therapy, while proteins enriched in SP fractions were related to energy metabolism and cytoskeleton dynamics. Proteins enriched in uEV after local prostate cancer treatment were mainly responsible for the classic transport function of EV.
INTRODUCTION AND OBJECTIVES: Hyperspectral imaging (HSI)
is an emerging modality used to obtain spatially resolved spectral images that provides diagnostic information on tissue physiology and morphology. The hyperspectral image data of prostate cancer tissues from prostatectomy specimen were analyzed to determine its clinical utility.
METHODS: After obtaining the institutional review board 0 s approval, 22 prostate cancer specimens obtained from radical prostatectomy were evaluated. A randomly selected square of 5Â5 mm pixel was identified on each specimen slices. We evaluated 209 pixels from 132 cancer and 77 normal areas. The prostatic glands were sliced at 4mm intervals perpendicular to the urethra. The HSI system was used to obtain hyperspectral images of the specimens. This system is capable of obtaining reflectance images with a size of 1920Â1440 over 400 to 700nm (Dl[15 nm) . CIELAB values represents colors using the coordinates in a uniform color space consisting of lightness variable L* and chromaticity indices a* and b*. CIELAB values are calculated as ([L*]2þ[a*]2þ[b*]2)1/2. The CIELAB of malignant and normal areas were calculated, respectively, and plotted in the color space. The association between CIELAB and tumor characters such as Gleason score (GS) classification was determined.
RESULTS: Higher GS of the cancer tissue was associated with a relatively high-intensity wavelength range. The mean CIELAB data were not significantly different between the normal areas and GS 3þ3 tumors (p[0.41). However, the mean CIELAB data of GS 3þ4!tumors were significantly higher than those of GS 3þ3 tumors (meanAESD, 67.5AE1. 
PD05-03 MOLECULAR HALLMARKS OF MPMRI VISIBILITY IN PROSTATE CANCER
Taylor Y. Sadun*, Los Angeles, CA; Kathleen E. Houlahan, Toronto, Canada; Amirali Salmasi, San Diego, CA; Aydin Pooli, Ely R. Felker, Steven S. Raman, Preeti Ahuja, Anthony E. Sisk, Paul C. Boutros, Robert E. Reiter, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Multiparametric MRI (mpMRI) has transformed prostate cancer (PCa) management by improving identification of clinically significant disease. However, w20% of primary prostate tumors are invisible to mpMRI. We hypothesize that differences in functional mpMRI visibility reflect fundamental molecular properties of a tumor.
METHODS: We profiled the transcriptomic and copy number profile of 40 Gleason Grade Group 2 tumors treated by prostatectomy. Twenty tumors were mpMRI invisible (PI-RADSv2: 1-2), while 20 tumors were visible (PI-RADsv2: 5).
RESULTS: Copy number aberrations (CNAs) and mRNA abundance were analyzed. Univariate analysis identified 102 transcripts differentially abundant between visible vs invisible tumors. Unexpectedly, non-coding transcripts comprised the majority of differentially abundant RNAs (57/102 transcripts). In particular, snoRNAs were significantly more likely to have elevated abundance in visible tumors (OR[4.4; . Perhaps most provocatively, SCHLAP1, a lncRNA linked to PCa progression, was more abundant in visible tumors (log2FC [3.2, FDR[0.028;  Figure 1A ). Additionally, visible tumors harbored significantly more unstable genomes, quantified as the percentage of the genome altered via CNAs (PGA; P[0.036; log2FC[2.3;  Figure 1B ). Concordantly, intraductal carcinoma (IDC) and cribriform architecture (CA) were enriched in PI-RADSv2 5 tumors (OR [ 7.0; P[0.031; Figure 1C ). Finally, we quantified a synergy between hallmarks and found the odds of visibility to be 10-fold higher with co-occurrence of !2 hallmarks (OR[10; P[5.7x10-3; Figure 1D ). Nimbosus hallmarks synergized with snoRNA levels to predict visibility with 87% accuracy, superior to the 60% accuracy of the clinical signature, suggesting elevated snoRNA abundance may be a novel hallmark of nimbotic tumors (AUC[0.87, 95% CI: 0.75-0.99; Figure 1E ).
CONCLUSIONS: This work points to a novel model for the origin of mpMRI visibility involving the co-occurrence of multiple aggressive hallmarks, reminiscent of nimbosus. These hallmarks include IDC/CA pathology, increased PGA and overexpression of key non-coding transcripts, such as SCHLAP1 and snoRNAs. This cooccurrence results in an aggressive tumor phenotype, with poor patient outcome.
